EMA Authorised: Evkeeza (Evinacumab) — Ultragenyx Germany GmbH

View source ↗

Summary

EMA authorised Evkeeza (evinacumab) by Ultragenyx Germany GmbH for the treatment of homozygous familial hypercholesterolemia, representing EU marketing authoriz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• Evkeeza (evinacumab)

Snippet

Status: Authorised. Therapeutic area: Hypercholesterolemia. MAH: Ultragenyx Germany GmbH. Decision date: 23/02/2026